Loading
A phase 1/2 trial of Trametinib in biliary tract cancer, run by Genfit, now recruiting.
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma is a phase 1/2 interventional study registered as NCT05874414 by Genfit, with 98 participants planned, started 2023-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: GNS561 + Trametinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/